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Introduction 
 
Over the last two decades, considerable attention has been focused on the relationship between carcinogen 
metabolism and cancer risk in humans. In particular, the association between carcinogenesis and the enzyme system 
responsible for the metabolism of most lypophilic chemicals, the cytochrome P-450 monooxygenases, has been 
addressed (1-4). This enzyme system is composed of numerous cytochrome P-450 isoenzymes that differ with 
respect to both substrate specificities and in their responses to enzyme inducers and inhibitors (1-6). In the case of 
aromatic amines and amides the first and obligatory step in their metabolic activation involves N-hydroxylation, and 
for the model hepatocarcinogen, 2-acetylaminofluorene (AAF), we have shown that a distinct isoenzyme of 
cytochrome P-450 in rabbit liver is involved in this process (7). This high degree of regio-selectivity of cytochrome 
P-450 isoenzymes in the oxidation of model carcinogens such as AAF (7) and benzo(a)pyrene (3) has provided the 
basis for the notion that the relative composition of cytochrome P-450 isoenzymes may be a major determinant in 
individual susceptibility to cancer as well as in target organ selection upon exposure to chemical carcinogens. 
In man, numerous studies have documented large inter-individual differences both in vivo and in vitro in 
activities associated with the cytochrome P-450 system (5). This variability in expression and/or intrinsic activity of 
cytochrome P-450 has in part been attributed to environmental factors, age, disease and drug therapy. Recent 
studies, however, have also demonstrated genetic variability in cytochrome P-450 mediated drug oxidation, 
particularly in the 4-hydroxylation of the antihypertensive agent debrisoquine (8). Two distinct phenotypes have 
been observed for the 4-hydroxylation of debrisoquine, designated extensive, and poor metabolizers, and a number 
of other drugs have been shown to be under the same monogenic control (8,9). The frequency of the poor 
metabolizer phenotype, depending on ethnic origin, has been shown to vary between 1-30070 of the population 
(8,9). This oxidative defect in debrisoquine metabolism has been linked to a deficiency or absence of a specific form 
of hepatic cytochrome P-450 (9,10). Further, those subjects of the poor metabolizer phenotype have been shown to 
exhibit increased pharmacodynamic and toxicity effects when administered drugs associated with this 
pharmacogenetic defect (8). In contrast to those side effects associated with the poor metabolizer defect, two recent 
studies by Idle and co-workers (11,12) have demonstrated disproportionate numbers of extensive metabolizers of 
debrisoquine in cancer groups compared to controls. These authors infer that the extensive metabolizer phenotype 
would be more likely to develop tumors due to their enhanced ability to activate chemical carcinogens. 
To test this hypothesis we assessed the capability of human liver microsomes from 28 individuals to 
metabolize debrisoquine and bufuralol, 2 drugs that show genetic variability in cytochrome P-450 dependent 
metabolisms in humans characterised by extensive and poor metabolizer phenotypes, as well as the 
hepatocarcinogen 2-acetylaminofiuorene. AAF was chosen as a substrate since recent studies in this laboratory have 
shown it to be a useful probe for determining multiple forms of cytochrome P-450 in human (13), rabbit (7) and rat 
(14) liver microsomes. The cytochrome P-450 mediated metabolism of AAF involves oxidation at both nitrogen and 
carbon atoms. The former leads to metabolic activation, while hydroxylation at positions 1, 3, 5, 7 and 9 on the 
fluorene ring are considered detoxification pathways (15). Therefore, the use of this substrate enables us to correlate 
pathways leading to metabolic activation and detoxification of a carcinogen, with debrisoquine 4-hydroxylation and 
bufuralol 1-hydroxylation. In addition, we determined aldrin epoxidation as an indicator of the activity of another 
unrelated isoenzyme of cytochrome P-450 (16) and measured cytochrome P-450 content of each microsomal 
preparation. 
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Materials and Methods  
 
Chemicals 
 
Randomly labelled [3H]AAF (18 Ci/mmol) was purchased from Moravek Biochemicals (Brea, CA) and was 
purified to greater than 98% purity by high-pressure liquid chromatography (14). Unlabelled AAF, 2-aminofluorene, 
N-hydroxy-AAF (N-OH-AAF), 1-hydroxy-AAF (1-OH-AAF), 3-hydroxy-AAF (3-OH-AAF), 5-hydroxy-AAF (5-
OHAAF), 7-hydroxy-AAF (7-OH-AAF), 9-hydroxy-AAF (9-OH-AAF), and 2-acetylaminofluorene-9-one were 
obtained as described previously (14). Desferrioxamine mesylate was purchased from Ciba Pharmaceuticals 
(Summit, N J) and NADPH from Sigma Chemical Co. (St. Louis, MO). Debrisoquine hemisulfate, bufuralol 
hydrochioride, and 1-hydroxybufuralol were generously provided by Roche Products, Ltd. (Welwyn Garden City, 
United Kingdom); [2H9]-4-hydroxy-debrisoquine was prepared biologically as described previously (16). Aldrin 
and the epoxide of aldrin, dieldrin, were a gift from the Shell Toxicology Laboratory (Sittingbourne, U.K.). 
 
Human Tissue Samples 
 
Microsomal fractions of human liver were obtained as described previously (16), either from wedge biopsy samples 
taken at laparotomy or from samples of liver of renal transplant donors maintained on life support systems until the 
kidneys could be removed. The use of such tissue in these studies had local Research Ethics Committee permission 
and where appropriate, Coroner's permission. Samples were stored at -80 ° until required, during which time there 
was no loss of activity. Liver samples from renal transplant donors had activities very similar to that of wedge 
biopsy samples with normal histology (16), and therefore no further distinction has been made between the 2 groups 
of samples in this study. 
 
Xenobiotic Assays 
 
AAF metabolism was measured essentially as described previously, except that sodium fluoride was omitted from 
the incubation mixture (14). Concentrations of AAF used were 0.37 and 50 /~M, and microsomal protein contents 
per ml of incubation mixture were 25 and 100/~g, respectively, at these concentrations. Two concentrations of AAF 
were used since we have shown previously that the relative quantity of each metabolite of AAF produced by human 
and rat liver microsomes and therefore the balance between metabolic activation (N-hydroxylation) and 
detoxification (C-hydroxylation) varied markedly with substate concentration (12,13). Debrisoquine 4-hydroxylase 
and bufuralol 1-hydroxylase activities were measured according to the methods of Kahn et al. (17) and Boobis and 
Davies (3), respectively. Aldrin epoxidation was measured according to the method of Wolff et al. (18). Incubation 
conditions used gave reaction rates that were zero order with respect to cofactor and linear with respect to protein 
concentration and time. Multiple crosscorrelations were calculated as described previously (16). 
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Results and Discussion 
 
The mean cytochrome P-450 content of the 28 human liver microsomes tested was 0.37±0.11 nmol per mg protein 
(mean±S.D.) and at the low concentration of AAF (0.37ttu) there were statistically significant correlations between 
cytochrome P-450 content and the rates of formation of some of the metabolites of AAF. Correlation coefficients 
ranged from 0.59 for 7-OH-AAF and cytochrome P-450, to 0.32 for 9-OH-AAF and cytochrome P-450. At 50/zM 
AAF only a significant correlation was observed between 7-OHAAF and cytochrome P-450 (r= 0.74). Table 1 
shows that except for the 3-hydroxylation of AAF, exceptionally high correlations (r > 0.94) existed between the 
rates of formation of individual metabolites of AAF at 0.37 µM (p < 0.05), and imply that similar forms of 
cytochrome P-450 produce these metabolites. However, at 50µM AAF correlations between rates of metabolite 
formation were considerably weaker than those at the low AAF concentration, suggesting different populations of 
cytochrome P-450 were involved in the formation of these metabolites at this concentration (16). 
The rates of formation of the different metabolites of AAF at 0.37 µM and 50 µM plotted against 
debrisoquine 4-hydroxylation, bufuralol 1-hydroxylation, and aldrin epoxidation are depicted in Figs. 1 and 2. 
Marked interindividual differences were observed in the rates of formation of different AAF metabolites at 0.37 µM 
with these being most marked for the N-hydroxylation (50-fold) and 1-hydroxylation (55-fold). Interindividual 
differences in debrisoquine, bufuralol and aldrin metabolism were 12-, 20- and 2.4-fold, respectively. The 4-
hydroxylation of debrisoquine was not correlated with cytochrome P-450 (r= 0.26) whereas both the 1-
hydroxylation of bufuralol (r= 0.45) and the epoxidation of aldrin (r=0.72) were correlated with this parameter. 
While bufuralol 1-hydroxylation was correlated with cytochrome P-450 content, the correlation only explained 20% 
of the total variance. Rates of debrisoquine and bufuralol metabolism were significantly correlated (r = 0.73) which 
supports the suggestion that a similar form of cytochrome P-450 catalyzes these reactions (9). 
N-hydroxylation is considered the first and obligatory step in the bioactivation of AAF and other aromatic 
amines and amides to their ultimate carcinogenic or mutagenic forms (14). At both concentrations of AAF used 
neither debrisoquine 4-hydroxylation nor bufuraiol 1-hydroxylation was correlated with AAF N-hydroxylation. 
Further, except for a weak correlation between 7-OH-AAF and bufuralol (r= 0.47) at 50 µM, no significant 
correlations were observed between debrisoquine and bufuralol metabolism and any of the C-hydroxylation 
pathways at the two substrate concentrations employed. This lack of correlation strongly suggests that different 
forms of cytochrome P-450 are involved in the metabolic activation and detoxification of this carcinogen compared 
to those oxidizing debrisoquine and bufuralol. 
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Probit plots of debrisoquine 4-hydroxylase and bufuralol 1-hydroxylase activities (data not shown) as well 
as cytochrome P-450 content (Fig. 3) of the 28 human liver samples tested were linear indicating that values were 
normally distributed about their respective means. However, similar analysis of AAF metabolism at 0.37 µM, a 
realistic environmental exposure level, showed distinct biphasic probit plots for both metabolic activation and 
detoxification pathways of this carcinogen (Fig. 3). Biphasic probit plots are indicative of two phenotypes for these 
activities being present in our population sample. For the N hydroxylation of AAF (metabolic activation) 79°70 of 
the sample were slow metabolizers and their values ranged from 2 to 31 pmol N-OH-AAF formed/min/mg protein. 
Values for the fast or extensive metabolizers ranged from 42 to 133 pmol/min/mg protein. The 1- and 7-
hydroxylations of AAF exhibited identical probit plots to N-hydroxy 2-acetylaminofluorene (Fig. 4) (19). However, 
the slow metabolizers for the formation of 9- and 3-hydroxy-acetylaminofluorene represented 89070 of the 
population (Fig. 4). 
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Despite the lack of correlation between either debrisoquine and bufuralol metabolism and AAF 
bioactivation or detoxification, these data nonetheless clearly demonstrate a metabolic polymorphism in human liver 
samples for AAF metabolism. The determinants of each phenotype for the metabolism of the carcinogen appear to 
be controlled by factors independent of those regulating debrisoquine 4-hydroxylation and bufuralol 1-
hydroxylation. Further the ultimate consequence of polymorphic bioactivation of chemical carcinogens in man is 
complicated by the possible existence of a metabolic detoxification polymorphism, as has been demonstrated in the 
present study with the model hepatocarcinogen 2-acetylaminofluorene. In general, we observed that individuals who 
were fast activators of the carcinogen were also fast detoxifiers of the chemical. However, the different phenotype 
patterns for N-hydroxylation and oxidation in the 3- and 9- positions  (relatively minor metabolites) suggest that fast 
activators of a toxin need not also be phenotyped as fast deactivators (19). Studies with other classes of carcinogens 
are required to further understand whether certain individuals may be more susceptible to chemical carcinogenesis 
because of their metabolic disposition. 
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